Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMRITA KRISHNAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1215948690
CMS profile
100883
Location
DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$83,995.08

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $19,257.64 10
E.R. Squibb & Sons, L.L.C. $18,800.35 14
GENZYME CORPORATION $15,624.64 10
Takeda Pharmaceuticals U.S.A., Inc. $13,556.70 9
PFIZER INC. $9,020.00 4
Adaptive Biotechnologies Corporation $7,283.85 5
Janssen Biotech, Inc. $252.98 2
Celgene Corporation $184.68 3
ABBVIE INC. $14.24 1

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMRITA KRISHNAN

NPI 1215948690 · CMS profile ID 100883

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $83,995.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $1,570.0003/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955690987 CMS
Takeda Pharmaceuticals U.S.A., Inc. $785.0002/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955690983 CMS
Takeda Pharmaceuticals U.S.A., Inc. $785.0002/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955690979 CMS
E.R. Squibb & Sons, L.L.C. $1,384.0002/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932511887 CMS
PFIZER INC. $4,000.0001/24/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949352817 CMS
E.R. Squibb & Sons, L.L.C. $1,800.0001/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932511875 CMS
PFIZER INC. $1,575.0001/06/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949352939 CMS
GENZYME CORPORATION $729.0001/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938812141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $100,097.55 81
PY2020 $67,281.85 33
PY2021 $87,071.39 46
PY2022 $83,995.08 58
PY2023 $114,463.47 36
PY2024 $115,244.26 35
PY2025 $102,830.04 44

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $948,287.79 59
PY2024 Recipient $1,050.44 2
PY2024 Principal investigator $1,690,121.58 68
PY2023 Principal investigator $1,425,000.66 61
PY2022 Principal investigator $3,544,545.63 69
PY2021 Principal investigator $3,255,137.11 46
PY2020 Principal investigator $1,576,434.72 37
PY2019 Principal investigator $842,078.21 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,454.00 12/29/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440146
Principal investigator 1 Janssen Research & Development, LLC $17,894.69 12/26/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175440319
Principal investigator 1 Janssen Research & Development, LLC $6,870.12 12/26/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175440563
Principal investigator 1 Janssen Research & Development, LLC $1,619.00 12/18/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440140
Principal investigator 1 Janssen Research & Development, LLC $4,132.00 12/15/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440434
Principal investigator 1 Janssen Research & Development, LLC $10,033.41 12/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175440900
Principal investigator 1 Janssen Research & Development, LLC $3,071.85 12/08/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402043
Principal investigator 1 Janssen Research & Development, LLC $12,270.00 12/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440176
Principal investigator 1 Janssen Research & Development, LLC $32,034.00 12/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440611
Principal investigator 1 Janssen Research & Development, LLC $3,757.83 11/10/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402060
Principal investigator 1 Janssen Research & Development, LLC $943.00 11/03/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175440368
Principal investigator 1 Janssen Research & Development, LLC $26,141.32 10/31/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175440829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,047.46 10/29/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 1223264982
Principal investigator 1 Janssen Research & Development, LLC $2,228.00 10/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440311
Principal investigator 1 Janssen Research & Development, LLC $2,929.43 10/13/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402104
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,209.49 10/08/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 1223264980
Principal investigator 1 Janssen Research & Development, LLC $9,816.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440018
Principal investigator 1 Janssen Research & Development, LLC $2,228.00 09/26/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440534
Principal investigator 1 Janssen Research & Development, LLC $4,065.00 09/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440295
Principal investigator 1 Genentech, Inc. $2,660.40 09/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211533056
Principal investigator 1 Genentech, Inc. $44,123.40 09/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211533060
Principal investigator 1 Janssen Research & Development, LLC $3,512.00 09/15/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402078
Principal investigator 1 Janssen Research & Development, LLC $4,576.00 08/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440249
Principal investigator 1 Janssen Research & Development, LLC $9,180.00 08/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440587
Principal investigator 1 Janssen Research & Development, LLC $37,500.00 08/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175440123
Principal investigator 1 Janssen Research & Development, LLC $200,046.89 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175440772
Principal investigator 1 Janssen Research & Development, LLC $3,786.83 08/06/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402027
Principal investigator 1 Janssen Research & Development, LLC $20,205.00 08/04/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440331
Principal investigator 1 Janssen Research & Development, LLC $3,699.00 07/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440106
Principal investigator 1 Janssen Research & Development, LLC $4,456.00 07/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440622
Principal investigator 1 Janssen Research & Development, LLC $464.39 07/11/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402098
Principal investigator 1 Janssen Research & Development, LLC $2,228.00 06/26/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440473
Principal investigator 1 Janssen Research & Development, LLC $797.00 06/26/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440487
Principal investigator 1 GlaxoSmithKline, LLC. $10,887.50 06/09/2025 Non-covered Recipient Entity
HRCE CORP
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192144787
Principal investigator 1 Janssen Research & Development, LLC $1,245.76 06/09/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,466.44 06/04/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 1223264930
Principal investigator 1 Janssen Research & Development, LLC $6,152.00 05/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440325
Principal investigator 1 Janssen Research & Development, LLC $4,456.00 05/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440755
Principal investigator 1 Janssen Research & Development, LLC $4,346.24 05/15/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402054
Principal investigator 1 Janssen Research & Development, LLC $47,613.00 05/12/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440736
Principal investigator 1 Janssen Research & Development, LLC $1,285.58 04/11/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402071
Principal investigator 1 Janssen Research & Development, LLC $5,706.00 04/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175440720
Principal investigator 1 Janssen Research & Development, LLC $5,064.00 03/31/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440580
Principal investigator 1 Janssen Research & Development, LLC $2,228.00 03/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440479
Principal investigator 1 Janssen Research & Development, LLC $9,952.99 03/14/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402038
Principal investigator 1 Genentech, Inc. $313.20 03/05/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211533053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $178,281.58 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Modular Phase I IIOpenlabelMulticenterStudytoEvaluatetheSafetyTolerabilityPharmacokineticsImmunogenicityPharmacodynamicsandPreliminaryEfficacyofAZD0305asMonotherapyorinCombinationwithAnticancerAgentinParticipantswithRelapsedorRefractoryMultipleMyeloma No dispute reported 06/30/2026 1185539379
Principal investigator 1 Janssen Research & Development, LLC $11,380.00 02/20/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440088
Principal investigator 1 Janssen Research & Development, LLC $2,020.00 02/20/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440336
Principal investigator 1 Janssen Research & Development, LLC $9,342.04 02/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175440862
Principal investigator 1 Janssen Research & Development, LLC $4,911.35 02/13/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402091
Principal investigator 1 Janssen Research & Development, LLC $25,158.00 02/06/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440157
Principal investigator 1 Janssen Research & Development, LLC $488.00 01/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175440568
Principal investigator 1 Janssen Research & Development, LLC $5,523.24 01/16/2025 Non-covered Recipient Entity
HOPE FOUNDATION FOR CANCER RESEARCH
Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. No dispute reported 06/30/2026 1175402033
Principal investigator 1 Janssen Research & Development, LLC $50,825.48 01/13/2025 Non-covered Recipient Entity
THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC
A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma No dispute reported 06/30/2026 1175377630
Principal investigator 1 Janssen Research & Development, LLC $514.73 01/13/2025 Non-covered Recipient Entity
THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC
A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma No dispute reported 06/30/2026 1175377654
Principal investigator 1 Janssen Research & Development, LLC $62,147.15 01/13/2025 Non-covered Recipient Entity
THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC
A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma No dispute reported 06/30/2026 1175377679
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 01/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 1223264904
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 1223264906